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79-y-old man presented with ob-
structive jaundice in July 2001 and
was diagnosed with carcinoma of
the head of the pancreas. He underwent a
total pancreatectomy, as well as resection of
the distal stomach, duodenum, spleen, and
gall bladder. Histology showed a 9 3 10 3
6.5–cm tumour at the head of the pancreas
that, upon microscopic examination, showed
a moderately differentiated invasive adeno-
carcinoma displaying a mixed papillary and
glandular growth pattern. The resection
margins were free of tumour, and all resected
lymph nodes were clear of metastases. The
patient developed diabetes following his
pancreatectomy and was started on insulin.
His diabetes was managed with human
isophane insulin injections, 18 units in the
morning, 6 units in the evening with HbA1c
of 8.2% (normal range 5.1%–6.4%).
In June 2003, the patient was noted to
have hepatomegaly on follow-up and was
found to have liver and portal lymph node
metastases on a computed tomography scan
of the abdomen (Figure 1). The result of the
carbohydrate antigen 19–9 test was elevated
at 139 U/ml (normal ,37 U/ml). Metastatic
adenocarcinoma was diagnosed, and the
patient opted for conservative management.
In January 2004, the patient was admit-
ted following an episode of loss of con-
sciousness. He was diagnosed with
hypoglycaemia with an unrecordable hae-
mastix reading on arrival and a random
plasma glucose level of 2.9 mmol/l after
receiving intravenous dextrose. His renal
function tests were normal, and liver
function tests were normal except for an
elevated alkaline phosphatase of 116 IU/l
(normal 40–100 IU/l). A short synacthen test
was normal. During admission, the patient
had further episodes of documented hypo-
glycaemia with plasma glucose down to 1.8
mmol/l. His insulin dose was therefore
reduced to isophane insulin 12 U once
daily.
The patient was admitted again in March
2004, following an episode of confusion
during which he stabbed himself with a
knife. He underwent emergency surgery for
haemostasis and removal of the knife. A
psychiatric evaluation after his operation
found no evidence of depression or suicidal
ideation.
The patient was transferred to the pallia-
tive care ward and was noted to have
recurrent episodes of hypoglycaemia despite
progressive reduction of his insulin dose to
isophane insulin 4 U daily. He was on no
other medications except frusemide for mild
ankle oedema. Liver function tests were
normal except for a mildly elevated alkaline
phosphatase of 144 IU/l (normal 40–100 IU/l).
The international normalised ratio was 1.26
(normal range 0.9–1.1). His chest x-ray was
normal.
In view of the recurrent episodes of
symptomatic hypoglycaemia, he was even-
tually taken off all insulin injections. A fasting
blood sample taken 2 d after stopping insulin
showed blood glucose 5.4 mmol/l, C-peptide
,0.5 lg/l (normal range 1.1–5 lg/l), and
insulin level ,2 mIU/l (normal range 6–35
mIU/l). Repeated urine analysis was negative
for ketones.
10 d after stopping insulin, the patient
developed further episodes of hypoglycae-
mia, with blood glucose levels of 1.7 mmol/l
and 2.1 mmol/l. Insulin levels were undetect-
able. A repeat short synacthen test showed a
raised baseline cortisol of 1,082 nmol/l
(reference range 171–536 nmol/l) and post-
stimulation cortisol of 1,145 nmol/l, indicat-
ing activation of the hypothalamic-pituitary-
adrenal axis from the recurrent hypoglycae-
mia. Insulin-like growth factor (IGF)-I level
was ,2 nmol/l (normal range 5–22.5 nmol/l).
Total IGF-II was 35.6 nmol/l. The IGF-II/IGF-I
ratio was raised, at .18 (normal ,10). The
PLoS Medicine | www.plosmedicine.org August 2006 | Volume 3 | Issue 8 | e331 1255
PLoS MEDICINEIGF-BP3 level was low, at 0.4 mg/l (normal 0.7–4.4 mg/l).
Growth hormone (GH) level was undetectable.
The patient was diagnosed as having non-islet cell tumour
hypoglycaemia (NICTH) due to metastatic adenocarcinoma.
His hypoglycaemic episodes were stabilized with an intra-
venous dextrose infusion, and the patient remained relatively
free of neuropsychiatric symptoms or psychospiritual dis-
tress. The patient eventually died of cancer cachexia 2 wk
later. An autopsy was not performed.
DISCUSSION
Spontaneous hypoglycaemia is suggested by the presence of
Whipple’s triad: symptoms suggestive of hypoglycaemia,
biochemical conﬁrmation of hypoglycaemia, and reversal of
symptoms following correction of hypoglycaemia. Neuro-
glycopenic symptoms tend to predominate as autonomic
warning symptoms, and counterregulatory hormonal re-
sponses are often impaired in the setting of recurrent
hypoglycaemia [1].
Hypoglycaemia in patients with cancer may be secondary
to medications, liver failure, renal failure, severe sepsis, or
adrenal insufﬁciency. In addition, NICTH is increasingly
recognized as an important cause of hypoglycaemia in such
patients. NICTH has been reported to occur in association
with a variety of malignant tumours, including hepatomas,
colorectal carcinomas, breast carcinomas, renal cell carcino-
mas, and lung carcinomas, as well as haematological
malignancies and benign tumours such as mesenchymal
ﬁbromas [2].
The occurrence of NICTH in association with adenocarci-
noma of the pancreas is extremely rare [3], but dramatically
illustrates the hypoglycaemic potential of the condition. In
our patient, who had undergone a total pancreatectomy
resulting in insulin deﬁciency and diabetes, the tumour was
able to cause reversal of his diabetes and induce recurrent
hypoglycaemia, even in the absence of any endogenous
insulin secretion.
The hypoglycaemia in NICTH is believed to be due to
tumour production of a prohormone form of IGF-II, termed
‘‘big’’ IGF-II. IGF-II is normally sequestered and inactivated
by binding to speciﬁc binding proteins such as IGF-BP3 to
form a 150-kD ternary complex. The elevated IGF-II levels
inhibit the secretion of endogenous insulin and GH. The low
GH levels in NICTH in turn result in decreased levels of IGF-
BP3, thereby impairing the formation of the ternary
complexes (Figure 2). As a result, a larger proportion of
IGF-II can circulate freely as binary complexes, which causes
hypoglycaemia by inhibiting hepatic glucose production and
enhancing glucose disposal to muscle [2].
The diagnosis of NICTH can be conﬁrmed by ﬁnding
suppressed insulin, C-peptide, and GH concentration in the
setting of hypoglycaemia (conﬁrmed by laboratory measure-
ment of blood glucose), along with elevated total and ‘‘big’’
IGF-II levels. A total IGF-II/IGF-I ratio of .10 is thought to be
diagnostic. It is important to take blood for the above
measurements (and in some cases, to screen for sulphonylur-
ea) at the time of symptomatic hypoglycaemia, and to
document symptoms and the response to glucose treatment.
Adrenal insufﬁciency due to adrenal metastases should be
excluded.
Surgical resection is the treatment of choice for tumours
causing hypoglycaemia due to NICTH, and should result in
normalization of blood glucose and the biochemical abnor-
mality. However, this may not be possible in patients with
metastatic disease. Debulking the tumour with radiotherapy
or chemotherapy has been reported to be effective in
controlling the hypoglycaemia [4]. If surgery is not feasible,
the hypoglycaemia can be treated with repeated glucagon
injections [5] or intravenous glucose. Glucocorticoids are very
effective in preventing hypoglycaemia and have been shown
to reduce tumour production of ‘‘big’’ IGF-II in a dose-
dependent manner [6]. A dose of prednisolone 30–60 mg/d or
dexamethasone 4 mg/d has been reported to be effective [7].
Recent advances in understanding the pathophysiology of
NICTH should be helpful for clinicians in the management of
recurrent hypoglycaemia in patients with cancer.
Figure 1. Enhanced Computed Tomography Scan of Abdomen
Enhanced computed tomography scan of abdomen showing hetero-
genous liver metastases with irregular rim enhancement as well as
hypodense lesions in the portal region suggestive of metastatic
lymphadenopathy.
DOI: 10.1371/journal.pmed.0030331.g001
Figure 2. Pathophysiology of NICTH
DOI: 10.1371/journal.pmed.0030331.g002
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Learning Points
 Hypoglycaemia in patients with known malignancy may be
due to medications, liver failure, renal failure, sepsis, adrenal
insufficiency, or NICTH.
 In the investigation of spontaneous hypoglycaemia, it is
important to document hypoglycaemia with a reliable labora-
tory blood glucose measurement and to take blood at the time
of hypoglycaemia for measurement of insulin, C-peptide, and
other hormones before treatment with glucose has been given.
 NICTH can occur in association with a variety of malignant
tumours, but can also occur secondary to haematological
malignancies and some benign mesenchymal tumours.
 The hypoglycaemia that occurs in NICTH is not dependent on
endogenous insulin secretion, but instead is caused by tumour
production of a prohormone form of IGF-II.
 Unprovoked hypoglycaemia or unexplained changes in insulin
sensitivity in a patient with known malignancy should alert
physicians to the possibility of NICTH.
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